Pharmacokinetics (PK) and pharmacodynamics (PD) characterization of mtor inhibitors in older adults
Active Cooperative Agreement Awarded Last action
- Award ID
- U01AG081450
- Recipient
-
The University Of Texas Southwestern Medical Center UEI YZJ6DKPM4W63
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,837,084
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 72% complete
- Place of performance
- Dallas, TX 75390, USA
Award details come from USAspending.gov.
Description
- Abstract
- Aging is the time-dependent functional decline responsible for increased susceptibility to chronic disease, frailty, and disability. Aging is a substantial public health concern, and new therapeutic interventions intended to mitigate its effects are needed. While preclinical evidence supports the crucial role of mtor inhibitors in slowing aging processes, the lack of pharmacokinetic (PK) and pharmacodynamic (PD) data in older adults presents a substantial challenge in designing clinical trials. Sirolimus and everolimus are well-studied mtor inhibitors commonly used in transplantation. However, both age and severe illness can significantly alter drug PK, and there is currently limited data in older adults without underlying, confounding illnesses. Additionally, there is a lack of data to inform the selection of PD biomarkers that optimally demonstrate improvement in age-related processes. Without well-defined PK characterization and identification of robust PD biomarkers, future clinical trials will lack the statistical power needed to establish evidence of effectiveness. To lay the foundation for future studies, we assembled a multidisciplinary team of clinical pharmacologists and epidemiologists, as well as experts in geriatrics, gerontology, and immunosuppression. The primary goal of this research is to precisely estimate fundamental PK/PD parameters of sirolimus and everolimus in older adults without confounding illness. We will first validate measurement techniques and quantify the in vitro exposure-response relationship for two different biomarkers: S6K activity and mitochondrial function (aim 1). We will then conduct a clinical study to characterize the PK/PD of sirolimus and everolimus in older adults (aim 2). Lastly, the biomarkers will be evaluated for their ability to demonstrate the magnitude of treatment response over an intermediate term follow-up (aim 3). We anticipate that our research will address the existing knowledge gaps related to mtor inhibitor PK/PD, leading to a transformative shift in the field of aging research.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $611,167 | |
| Amendment | $0 | |
| Amendment | $607,516 | |
| Original award | $618,401 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| University Of Maryland, Baltimore | $873,103 |
Quick answers
Who received award U01AG081450?
U01AG081450 was awarded to The University Of Texas Southwestern Medical Center by National Institute on Aging (National Institutes of Health) on September 1, 2024.
How much is award U01AG081450 worth?
$1,837,084 has been obligated on U01AG081450.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award